LifeValve was a collaborative project funded by the European Commission under the Seventh European Framework Programme and brought together a unique consortium of academic and industrial partners from Switzerland (Leading House), Germany, The Netherlands, Austria and Hungary. The principal objective of the LifeValve project was to develop a new therapeutic strategy to treat heart valve disease patients more efficiently.
The scientific and technological approach of the LifeValve project were to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growth which can be implanted by minimally invasive catheter technology. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. The compact consortium is well interconnected and comprises all the necessary expertise and skills to realize the precisely planned work in a timeline of five years.
The European consortium was led and coordinated by Simon P. Hoerstrup and his Regenerative Medicine group in Zurich.